Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2021 - 07 - 22 save search
UFPI board approves quarterly dividend of $0.15 per share
Published: 2021-07-22 (Crawled : 22:00) - globenewswire.com
UFPI 4 | $111.71 0.96% 0.95% 310K
|
Non-Energy Minerals
|
| O: 0.38%
H: 0.7%
C: -0.59%
approval
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
Published: 2021-07-22 (Crawled : 21:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: -1.69%
cancer leukemia
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
Published: 2021-07-22 (Crawled : 15:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.0%
H: 1.65%
C: -0.06%
food phase 1 lenzilumab drug approval phase 2
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
Published: 2021-07-22 (Crawled : 12:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 15.43%
H: 56.64%
C: 40.96%
covid approval aviptadil commercialization
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Published: 2021-07-22 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.27%
H: 0.25%
C: -0.09%
fda trial fda approval keytruda
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-22 (Crawled : 11:36) - fda.gov
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.0%
H: 1.02%
C: 0.51%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 1.28%
C: 1.22%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.18%
H: 0.31%
C: -2.26%
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
|
| O: -1.57%
H: 3.71%
C: 0.43%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.12%
C: -0.6%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.36%
H: 1.56%
C: 0.9%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -3.01%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.39%
H: 0.11%
C: -0.27%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -1.49%
H: 2.0%
C: -2.34%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.0%
H: 0.58%
C: -3.46%
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.84%
H: 1.72%
C: 0.61%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 2.21%
H: 0.0%
C: -4.87%
cancer approval
Cybin Announces Conditional Listing Approval from NYSE American
Published: 2021-07-22 (Crawled : 07:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
| Email alert
Add to watchlist
approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.